350 related articles for article (PubMed ID: 17932682)
1. alpha-Synucleinopathy models and human neuropathology: similarities and differences.
Kahle PJ
Acta Neuropathol; 2008 Jan; 115(1):87-95. PubMed ID: 17932682
[TBL] [Abstract][Full Text] [Related]
2. Nuclear and neuritic distribution of serine-129 phosphorylated alpha-synuclein in transgenic mice.
Schell H; Hasegawa T; Neumann M; Kahle PJ
Neuroscience; 2009 Jun; 160(4):796-804. PubMed ID: 19272424
[TBL] [Abstract][Full Text] [Related]
3. Age-dependent cognitive decline and amygdala pathology in alpha-synuclein transgenic mice.
Freichel C; Neumann M; Ballard T; Müller V; Woolley M; Ozmen L; Borroni E; Kretzschmar HA; Haass C; Spooren W; Kahle PJ
Neurobiol Aging; 2007 Sep; 28(9):1421-35. PubMed ID: 16872721
[TBL] [Abstract][Full Text] [Related]
4. Alpha-synuclein transgenic mice: relevance to multiple system atrophy.
Fillon G; Kahle PJ
Mov Disord; 2005 Aug; 20 Suppl 12():S64-6. PubMed ID: 16092093
[TBL] [Abstract][Full Text] [Related]
5. Neuropathological spectrum of synucleinopathies.
Jellinger KA
Mov Disord; 2003 Sep; 18 Suppl 6():S2-12. PubMed ID: 14502650
[TBL] [Abstract][Full Text] [Related]
6. Motor impairment and aberrant production of neurochemicals in human alpha-synuclein A30P+A53T transgenic mice with alpha-synuclein pathology.
Ikeda M; Kawarabayashi T; Harigaya Y; Sasaki A; Yamada S; Matsubara E; Murakami T; Tanaka Y; Kurata T; Wuhua X; Ueda K; Kuribara H; Ikarashi Y; Nakazato Y; Okamoto K; Abe K; Shoji M
Brain Res; 2009 Jan; 1250():232-41. PubMed ID: 18992718
[TBL] [Abstract][Full Text] [Related]
7. A systematic RNAi screen reveals involvement of endocytic pathway in neuronal dysfunction in alpha-synuclein transgenic C. elegans.
Kuwahara T; Koyama A; Koyama S; Yoshina S; Ren CH; Kato T; Mitani S; Iwatsubo T
Hum Mol Genet; 2008 Oct; 17(19):2997-3009. PubMed ID: 18617532
[TBL] [Abstract][Full Text] [Related]
8. Alpha-synuclein and transgenic mouse models.
Fernagut PO; Chesselet MF
Neurobiol Dis; 2004 Nov; 17(2):123-30. PubMed ID: 15474350
[TBL] [Abstract][Full Text] [Related]
9. Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation.
Uversky VN
J Neurochem; 2007 Oct; 103(1):17-37. PubMed ID: 17623039
[TBL] [Abstract][Full Text] [Related]
10. The emerging role of α-synuclein truncation in aggregation and disease.
Sorrentino ZA; Giasson BI
J Biol Chem; 2020 Jul; 295(30):10224-10244. PubMed ID: 32424039
[TBL] [Abstract][Full Text] [Related]
11. Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology.
Ulusoy A; Febbraro F; Jensen PH; Kirik D; Romero-Ramos M
Eur J Neurosci; 2010 Aug; 32(3):409-22. PubMed ID: 20704592
[TBL] [Abstract][Full Text] [Related]
12. A molecular pathway of neurodegeneration linking alpha-synuclein to ApoE and Abeta peptides.
Gallardo G; Schlüter OM; Südhof TC
Nat Neurosci; 2008 Mar; 11(3):301-8. PubMed ID: 18297066
[TBL] [Abstract][Full Text] [Related]
13. Intracranial administration of alpha-synuclein fibrils in A30P-synuclein transgenic mice causes robust synucleinopathy and microglial induction.
Gentzel RC; Toolan D; Jinn S; Schachter JB; Ma L; Kahle PJ; Smith SM; Marcus JN
Neurobiol Aging; 2021 Oct; 106():12-25. PubMed ID: 34225000
[TBL] [Abstract][Full Text] [Related]
14. Lewy body/alpha-synucleinopathy in schizophrenia and depression: a preliminary neuropathological study.
Jellinger KA
Acta Neuropathol; 2009 Apr; 117(4):423-7. PubMed ID: 19198857
[TBL] [Abstract][Full Text] [Related]
15. Isomers of human alpha-synuclein stabilized by disulfide bonds exhibit distinct structural and aggregative properties.
Jiang C; Chang JY
Biochemistry; 2007 Jan; 46(2):602-9. PubMed ID: 17209570
[TBL] [Abstract][Full Text] [Related]
16. [Neuropathology of tauopathies and synucleinopathies, and neuroanatomy of sleep disorders: meeting the challenge].
Hauw JJ; Hausser-Hauw C; Duyckaerts C
Rev Neurol (Paris); 2003 Nov; 159(11 Suppl):6S59-70. PubMed ID: 14646802
[TBL] [Abstract][Full Text] [Related]
17. Protein aggregation mechanisms in synucleinopathies: commonalities and differences.
Beyer K; Ariza A
J Neuropathol Exp Neurol; 2007 Nov; 66(11):965-74. PubMed ID: 17984679
[TBL] [Abstract][Full Text] [Related]
18. Carboxy-terminal truncation and phosphorylation of α-synuclein elongates survival in a prion-like seeding mouse model of synucleinopathy.
Sorrentino ZA; Hass E; Vijayaraghavan N; Gorion KM; Riffe CJ; Dhillon JS; Giasson BI
Neurosci Lett; 2020 Jul; 732():135017. PubMed ID: 32371157
[TBL] [Abstract][Full Text] [Related]
19. [Modelling synucleinopathies in genetically modified animals--successes and failures].
Ninkina NN; Ustiugov AA; Bukhman VL
Mol Biol (Mosk); 2008; 42(5):840-55. PubMed ID: 18988533
[TBL] [Abstract][Full Text] [Related]
20. Functional protein kinase arrays reveal inhibition of p-21-activated kinase 4 by alpha-synuclein oligomers.
Danzer KM; Schnack C; Sutcliffe A; Hengerer B; Gillardon F
J Neurochem; 2007 Dec; 103(6):2401-7. PubMed ID: 17883396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
